Rituximab in Combination With Bortezomib, Plasmapheresis, and High-Dose IVIG to Treat Antibody-Mediated Renal Allograft Rejection

BACKGROUND: Current treatment strategies for antibody-mediated renal allograft rejection (AMR) are not sufficiently effective. In most centers, “standard of care” treatment includes plasmapheresis (PPH) and IVIG preparations. Since several years, modern therapeutics targeting B cells and plasma cell...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Transplant Direct
Prif Awduron: Waiser, Johannes, Duerr, Michael, Schönemann, Constanze, Rudolph, Birgit, Wu, Kaiyin, Halleck, Fabian, Budde, Klemens, Lachmann, Nils
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Lippincott Williams & Wilkins 2016
Pynciau:
Kidney Transplantation
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5083001/
https://ncbi.nlm.nih.gov/pubmed/27819032
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/TXD.0000000000000604
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg